Vanguard Group’s Phio Pharmaceuticals PHIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $92K | Hold |
87,628
| – | – | ﹤0.01% | 4186 |
|
|
2025
Q3 | $217K | Buy |
87,628
+38,963
| +80% | +$88.7K | ﹤0.01% | 4116 |
|
|
2025
Q2 | $114K | Buy |
+48,665
| New | +$98.5K | ﹤0.01% | 4141 |
|
|
2024
Q3 | – | Sell |
-2,709
| Closed | -$16.9K | – | 4374 |
|
|
2024
Q2 | $16.9K | Hold |
2,709
| – | – | ﹤0.01% | 4365 |
|
|
2024
Q1 | $16.6K | Hold |
2,709
| – | – | ﹤0.01% | 4405 |
|
|
2023
Q4 | $18.5K | Hold |
2,709
| – | – | ﹤0.01% | 4452 |
|
|
2023
Q3 | $36.8K | Hold |
2,709
| – | – | ﹤0.01% | 4443 |
|
|
2023
Q2 | $70K | Buy |
2,709
+1,567
| +137% | +$55K | ﹤0.01% | 4422 |
|
|
2023
Q1 | $57.8K | Sell |
1,142
-289
| -20% | -$15.3K | ﹤0.01% | 4457 |
|
|
2022
Q4 | $57.5K | Sell |
1,431
-589
| -29% | -$30.2K | ﹤0.01% | 4432 |
|
|
2022
Q3 | $125K | Sell |
2,020
-739
| -27% | -$56K | ﹤0.01% | 4473 |
|
|
2022
Q2 | $210K | Sell |
2,759
-57
| -2% | -$5.36K | ﹤0.01% | 4463 |
|
|
2022
Q1 | $269K | Buy |
2,816
+178
| +7% | +$16.9K | ﹤0.01% | 4491 |
|
|
2021
Q4 | $285K | Hold |
2,638
| – | – | ﹤0.01% | 4522 |
|
|
2021
Q3 | $578K | Buy |
2,638
+77
| +3% | +$16.1K | ﹤0.01% | 4359 |
|
|
2021
Q2 | $625K | Buy |
2,561
+1,425
| +125% | +$351K | ﹤0.01% | 4234 |
|
|
2021
Q1 | $329K | Buy |
1,136
+456
| +67% | +$152K | ﹤0.01% | 4200 |
|
|
2020
Q4 | $198K | Buy |
+680
| New | +$172K | ﹤0.01% | 4086 |
|
|
2020
Q1 | – | Sell |
-4
| Closed | -$5K | – | 4091 |
|
|
2019
Q4 | $5K | Hold |
4
| – | – | ﹤0.01% | 4121 |
|
|
2019
Q3 | $7K | Hold |
4
| – | – | ﹤0.01% | 4149 |
|
|
2019
Q2 | $10K | Hold |
4
| – | – | ﹤0.01% | 4162 |
|
|
2019
Q1 | $12K | Hold |
4
| – | – | ﹤0.01% | 4110 |
|
|
2018
Q4 | $9K | Sell |
4
-1
| -20% | -$2.36K | ﹤0.01% | 4143 |
|
|
2018
Q3 | $35K | Buy |
5
+1
| +25% | +$9.41K | ﹤0.01% | 4142 |
|
|
2018
Q2 | $50K | Buy |
4
+1
| +33% | +$14.8K | ﹤0.01% | 4101 |
|
|
2018
Q1 | $59K | Buy |
+3
| New | +$69K | ﹤0.01% | 4062 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 4054 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 4067 |
|
|
2017
Q2 | – | Sell |
-2
| Closed | -$74K | – | 4068 |
|
|
2017
Q1 | $75K | Hold |
2
| – | – | ﹤0.01% | 4003 |
|
|
2016
Q4 | $66K | Buy |
2
+1
| +100% | +$78.2K | ﹤0.01% | 4008 |
|
|
2016
Q3 | $162K | Sell |
1
-1
| -50% | -$135K | ﹤0.01% | 3935 |
|
|
2016
Q2 | $235K | Hold |
2
| – | – | ﹤0.01% | 3915 |
|
|
2016
Q1 | $247K | Buy |
2
+1
| +100% | +$176K | ﹤0.01% | 3924 |
|
|
2015
Q4 | $340K | Hold |
1
| – | – | ﹤0.01% | 3911 |
|
|
2015
Q3 | $323K | Hold |
1
| – | – | ﹤0.01% | 3951 |
|
|
2015
Q2 | $268K | Hold |
1
| – | – | ﹤0.01% | 3995 |
|
|
2015
Q1 | $226K | Buy |
+1
| New | +$709K | ﹤0.01% | 3979 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 3821 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 3794 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 3861 |
|
Other funds holding PHIO
DS
SG
RSWM
VF
Vanguard Group's PHIO Position: Q4 2025 in Review
Vanguard Group held its Phio Pharmaceuticals (PHIO) position steady in Q4 2025 at 87,628 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #4186.
Vanguard Group first reported a position in PHIO in Q1 2015 and has held it in 35 quarters since. The position peaked at $625K in Q2 2021. 17 funds tracked by Wall St. Rank hold PHIO as of Q4 2025.
- Vanguard Group held 87,628 shares of Phio Pharmaceuticals worth $92K as of Q4 2025.
- Vanguard Group left its Phio Pharmaceuticals share count unchanged in Q4 2025.
- Phio Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #4186 holding.
- Vanguard Group first reported a position in Phio Pharmaceuticals in Q1 2015 and has held it in 35 quarters since.
- Vanguard Group's Phio Pharmaceuticals position peaked at $625K in Q2 2021.
- 17 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.